155P Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC)
نویسندگان
چکیده
BackgroundHER2 is an important predictive biomarker of HER2-targeted therapies for breast cancer. Reliable HER2 testing essential clinical practice, but immunohistochemistry (IHC) staining results are susceptible to considerable interobserver variations.MethodsWhole-slide images (WSI) pretreatment IHC- and H&E-stained slides, clinicopathological data were obtained from stage I – III, HER2-positive cancer patients treated with NAC including anti-HER2 agents at Samsung Medical Center, in Seoul, Korea, between 2009 2017. Lunit SCOPE AI-powered IHC analyzer, developed 1,133 stained WSI cancer, annotated by 113 board-certified pathologists. It classifies tumor cells intensity (H0, H1, H2 or H3) quantifies the each category. Also, it calculates AI categories accordance latest ASCO/CAP evaluation algorithm. IO a separate analyzer that identifies TIL within epithelium stroma WSI.ResultsTable: 155PpCR (+)pCR (-)p-valueH3 proportion, mean84.7%76.7%0.010Stromal (/mm2), mean1332888< 0.001Intratumoral mean218120< 0.001 Open table new tab ConclusionsAI-powered automated scoring analysis can provide additional information response prediction early NAC.Legal entity responsible studyLunit Inc.FundingLunit Inc.DisclosureY. Lim: Financial Interests, Personal, Full part-time Employment: Inc., IMBdx. S.I. Cho: Inc.; Stocks/Shares: Inc. S. Kim, G. Park, Song, H. W. Jung, K. Paeng: M. Ma: Lunit; Lunit. C. Ock: Invited Speaker: Ybiologics; Ybiologics. All other authors have declared no conflicts interest. variations. MethodsWhole-slide WSI. Whole-slide ResultsTable: NAC.
منابع مشابه
Neoadjuvant Therapy for HER2-positive Breast Cancer.
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and - depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates...
متن کاملPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
The primary goals when treating patients with metastatic breast cancer are to improve both duration and quality of life. With cytotoxic chemotherapy, this is typically achieved by using single agents sequentially (rather than combination regimens), switching therapies in the face of disease progression or prohibitive toxicity. This approach is supported by clinical trial data showing that chemo...
متن کاملTargeted therapy for HER2 positive breast cancer
INTRODUCTION Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45-55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two hallmark time frames. The first occurred during the mid to late 1980's when ho...
متن کاملNeoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
Approximately 20%-25% of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, resulting in an overexpression of the HER2 receptor. This overexpression is associated with aggressive disease, relatively poor prognosis, and worse clinical outcomes. Neoadjuvant therapy is the standard treatment in patients with locally advanced, inflammatory, or ...
متن کاملExpression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
PURPOSE The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms. Myxovirus resistance A (MxA) is an excellent marker of interferon activity. Here,we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. MATERI...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.07.190